NCT07173686View on ClinicalTrials.gov

Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy

Not yet recruitingOBSERVATIONAL

Enrollment

80

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

November 1, 2026

Conditions

Diabetic Nephropathy

All Listed Sponsors

lead

Assiut University

OTHER

NCT07173686 - Evaluating The Roles of Novel Inflammatory Markers Compared to MCP-1 in Type 2 Diabetic Nephropathy | Biotech Hunter | Biotech Hunter